Abstract: Transgenic Caenorhabditis elegans animals have been engineered to express wild-type and single-
A defining characteristic of Alzheimer' s disease (AD) is the presence of senile plaques in the brain. Many lines of evidence support the idea that deposition of /3-amyloid peptide (A/I), a primary component of senile plaques, is central to the neuropathology of AD (Selkoe, 1997) . Aggregation of A/3 into insoluble amyloid fibrils is strongly correlated with neurotoxicity both in vitro and in vivo, and synthetic A13 or A/I subpeptides can be toxic to cells in culture (for review, see Iverson et al., 1995) . In vitro neurotoxicity is dependent upon the aggregation state of A,@ (Pike et a!., 1991; Ueda et a!., 1994; Soto and Frangione, 1995) , and molecules that interfere with its aggregation all appear to inhibit in vitro neurotoxicity (Lorenzo and Yankner, 1994; Tomiyama et al., 1994; Ghanta et a!., 1996; Salomon eta!., 1996; Soto et a!., 1996; Tjernberg et al., 1996; Tomiyama et a!., 1996; Kihara et a!., 1997) . In the AD brain, the longer, more amyloidogenic forms of A/I (terminating at residue 42 or 43) are a critical component of senile plaques (Gravina et a!., 1995) . These forms are also specifically depleted in the soluble A/I from the cerebrospinal fluid of AD patients (Motter et al., 1995; Tamaoka et a!., 1997) .
In addition, early-onset AD mutations in the amyloid precursor protein (APP) gene (Suzuki et a!., 1994) or presenilin genes PS-i (Borchelt et al., 1996; Lemere et a!., 1996) and PS-2 (Mann et a!., 1997) all lead to increased production of the longer forms of A/I.
Understanding the structure of soluble and aggregated A/I is critical to determining the mechanism(s) of Aj3 toxicity. Unfortunately, the inability to crystallize A/3 has precluded direct structural determinations by x-ray crystallography. However, studies have shown that the conversion of soluble A/I to an aggregated form involves a shift from an a-helix/random coil state to one with significant /3-sheet structure, consistent with the known /3-sheet conformation of amybid fibrils (Simmons et a!., 1994; Soto and Frangione, 1995; Soto et al., 1995a,b; Terzi et al., 1995) . These studies and predictions based on primary sequence have produced structural models for A/3 ( Fig. 1 ) (Wisniewski eta!., 1994 ). Multiple groups have tested these models by assaying the aggregation of wild-type and variant forms of synthetic A/I or A/I subpeptides. For example, Wood and colleagues (1995) used scanning proline substitutions in A/I subpeptides to implicate the role of A/I residues 17-23 in amyloid formation. Pike and co-workers (1993) established that C-terminal subfragments of synthetic A/I, particularly A/I 25-35, can also form insoluble aggregates in vitro.
These studies raise two concerns: (a) Subpeptide fragments of /3 peptide might not extrapolate to the full-length molecule; and (b) because the structure of A/I peptides can be strongly influenced by lipids and the hydrophobicity of the environment (Shen and Murphy, 1995; Sticht et al., 1995; Kohno et al., 1996) , in vitro assays may not reflect the true characteristics of FIG. 1. Model of secondary structure of amyloidic A/3. Shown is the primary sequence of A/I 1-42 folded into one possible secondary structure, illustrating a potential N-terminal a helix and two /3 sheets. Circled residues indicate sites of substitutions described in the text. This figure is adapted from Wisniewski et al. (1994) .
A/I in vivo. We have thus developed an in vivo model for assaying the amyboid formation of wild-type and single-residue variant A/I 1-42. This model employs transgenic Caenorhabditis elegans expressing human A/I (Link, 1995) and has allowed us to assay the aggregation of a previously untested A/I variant, the singlechain /3 dimer.
MATERIALS AND METHODS

Construction of transgenes
Transgenes expressing A/I variants were derived from the previously described unc-54/A/I 1-42 construct pCL12 (Link, 1995) . The five single-amino acid variants were generated using the Chameleon Double-Stranded, Site-Directed Mutagenesis Kit from Stratagene. Protocols were carried out according to manufacturer's recommendations except that endonuclease digests were carried out overnight (as opposed to 1 h). ApaI was chosen to be the selector site in plasmid pCL12. The selectorprimer sequence (used for a!! reactions) P-CTAGTCGGCCGTACGCGCGCTTTCGTCTC differed from the homologous sequence in pCL 12 in that it does not contain an ApaI site. The mutagenic primers were as follows: Leu t7Pro (pDF2) P-GTTCATCATCAAAAACCG-GTGTTC'flTTGCAG; Leu'7Val (pDF3) P-GTTCATCAT-CAAAAAGTGGTGTTCTTTGCAG; Ala30Pro (pDF4) P-GGTFCAAACAAAGGTCCAATCATrGGACTC; Met35-Leu (pDF5) P-ATCATTGGACTCCTGGTGGGCGGTG-TTG; Met35Cys (pDF6) P-CAATCATTGGACTCTGCG-TGGGCGGTGTTG. Potential subcbones containing the specific mutations were screened initially by cutting with ApaI.
Clones that failed to cut with ApaI were sequenced to identify plasmids containing the desired mutations.
The single-chain A/I-dimer construct (pDF1) was constructed by using PCR to generate A/I-coding fragments from pCL12 that contained carboxy-or amino-terminal extensions that together encoded the 15-residue linker~e-quence (Gly -Gly -Gly -Gly-Ser-Gly-Gly-Ser-Gly-Gly-GlyGly-Ser-Gly-Gly). PCR reactions were carried out as follows: reaction 1: forward primer (GGGGATCCGGA-GGTGGAGGTAGCGGGGGGGATGCAGAATTCCGAC -ATG) and reverse primer (CCCGAGCTCACGCTATGA-CAACACCGCCCA); reaction 2: forward primer (GGG-GGTACCGATGCAGAAYTCCGACATGA) and reverse primer (GGGGATCCTCCACTCCCGCCACCT C C C GC -TATGACAACACCGCC). Reactions contained 1~ig of each primer, 100 ng of pCL12 template, 1~slof dNTPs (25 mM each), 1~il (2.5 U) of PJi~polymerase (Stratagene), 5 j.tl of Pfu lOx buffer, and 31~.tlof double-distilled H 20. Reactions were kept on ice until the program was initiated. Reactions were carried out as follows: 94°C,5 mm (1 cycle); 94°C, 1 mm, 55°C,1 mm, 72°C, 3 mm (30 cycles); 72°C, 5 mm (1 cycle); followed by maintenance at 4°C.
PCR products were then separated on a 1.5% agarose gel; 175-and 285-bp fragments were excised from reactions 1 and 2, respectively, and purified using the QlAquick protocol from Qiagen. The l75-bp fragment was digested with Sad and BamHI and repurified as described above. The 285-hp fragment was digested with NheI and BamHI and repurified. A three-part ligation was set up using NheIISacI-cut pCL12 and the cut and purified products from PCRs 1 and 2. Sequencing was used to confirm the expected nucleotide sequence of all regions within the plasmid generated by PCR.
Construction of transgenic strains
Heritable transgenic lines were constructed by DNA microinjection as previously described (Link, 1995) . A/I-expressing transgenes were co-injected with plasmids expressing the dominant morphological marker rol-6 (pRF4) (Mello et a!., 1991) or green fluorescent protein (GFP; pCL25), and transgenic animals were identified by following the coinjected marker. Expression of the pRF4 rol-6 marker gene causes transgenic animals to rotate around their longitudinal axis, resulting in distinctive nonsinusoidal movement. pCL25 expresses GFP under the control of the metallothionein promoter mtl-2 and leads to constitutive intestinal-specific expression of GFP in all postembryonic stages. We found the mtl-2IGFP marker to be particularly advantageous as it apparently has no physiological effects on transgenic animals and can be followed in young larval animals. Strains containing chromosomally integrated transgenes were generated by y irradiation and subsequent screening for completely stable lines. All integrated strains were outcrossed at least three times before being analyzed.
Histochemistry and immunohistochemistry
For thioflavin S staining, individual transgenic animals were fixed in 4% paraformaldehyde/phosphate-buffered saline (PBS; 125 mM NaC!, 16 mM Na2HPO4, 8 mM NaH2-P04W 2H20, pH 7.4) for 24 h at 4°C,then permeabilized by incubation in a 20-pi drop of permeabilization solution (5% fresh /I-mercaptoethanol, 1% Triton X-100, 125 mM Tris, pH 7.4) for 24 h in a humid chamber at 37°C.Permeabilized animals were hand-transferred to a drop of PBS, stained by transfer to 0.125% thioflavin S (Sigma) in 50% ethanol for 2 mm, destained for 2 mm in 50% ethanol, and returned to PBS before being mounted on 2% agarose pads for microscopy.
For Congo red staining, 50-100 transgenic animals were transferred to a 2.5-gil drop of H 20 in a 14-mm circle on a Teflon-printed microscope slide, compressed with a coyerslip, and quick-frozen on a block of dry ice. The coverslip was cracked off with a scalpel, and the still-frozen animals were repeatedly sliced with the scalpel. The cleaved animals were then quickly dried onto the slide by incubation on a 55°Cheating block (-30 s), and a 25-~.t1drop of 0.5% Congo red (Sigma) in 50% ethanol/lO mM Tris (pH 7.5) was added. After a 3-h incubation in a humid chamber at 20°C,the staining solution was removed by immersion in H 90, and a 25-j.il drop of fresh destaining solution (0.5% potassium hydroxide and 80% ethanol) was placed on the slide. Destaining was monitored under the dissecting microscope, and the slide was immersed in H20 as soon as dark red precipitates were observed (--40 s). A second drop of destain was added, and after 10 s the slide was again washed in H20. Immediately after drying, a S-pl drop of mounting medium (Molecular Probes) and a coverslip were added. Slides were observed with a Zeiss Axioskop compound microscope configured for polarization optics.
Immunohistochemistry was performed as previously described (Link, 1995) , except that anti-A/I monoclonal antibody 4G8 (Kim et a!., 1988 ; purchased from Senentek) was used as the primary antibody (at 5~sg/ml), and an Oregon Green-conjugated goat anti-mouse IgG secondary antibody (Molecular Probes) was used (at 20~g/ml) for some experiments. Images were collected on 35-mm slide film and digitally scanned, and brightness, color balance, and contrast were adjusted using Adobe Photoshop.
Immunoblots
Bicine/Tris sodium dodecyl sulfate (SDS) -polyacrylamide gel electrophoresis was carried out according to Klafki et a!. (1996) and Wi!tfang et a!. (1997) with the following exceptions: An acrylamide stock solution of 40% T/5% C (Accuge!; National Diagnostics) was used for all gel solutions. The final concentration of the separation gel was 18% T/5% C with respect to acrylamide/bisacrylamide and 21% with respect to glycerol. The comb gel contained 0.005% bromopheno! blue (final concentration), and the ammonium persulfate and TEMED (N,N,N',N'-tetramethylenediamine) were adjusted to 12~.tland 3~ilper 2 ml of gel solution, respective!y.
Young adult C. elegans organisms were transferred from NGM plates to microfuge tubes containing 5-10~ilof water, frozen in liquid nitrogen, and stored at -80°C. An equal volume of 2x sample buffer was added to the tubes while still frozen (lx sample buffer: 0.36 M Bis/Tris, 0.16 M bicine, 1% SDS, 15% sucrose, 2.5% 2-mercaptoethanol, 0.004% bromophenol blue), and the samples were boiled for 5 mm and then loaded onto the gel. Low molecular mass Rainbow Markers (Amersham) were used as approximate size standards. Three dilutions of synthetic A/I 1-40 (Bachem) were also included on each gel for quanlitation. A Hoefer Mighty Small Gel II was used for electrophoresis. The gels were run at 70 V until the samples reached the separating gel, at which time the voltage was increased to 100 V. Gels were transferred to a O.2-~mnitrocellulose membrane (NitroPure; MSI) in a Bio-Rad Transblot apparatus for 1.3 h at 21 V. The transfer buffer was 39 mM glycine, 48 mM Tris, and 20% methanol.
Following transfer, the blots were allowed to dry and then were boiled for 3 mm in PBS (Wiltfang et a!., 1997) . Blots were blocked for 2-4 h at room temperature or at 4°Cover-night in TBST (100 mM Tris, pH 7.5, 150 mM NaC1, 0.1% Tween) with 5% dry milk (TBST-M). Blots were incubated for 1.5 h in primary antibody 4G8 at a dilution of 1:400 in TBST-M. Following three washes in TBST-M, blots were incubated for 1 h in peroxidase-conjugated anti-mouse IgG (Sigma) at a dilution of 1:1,000 in TBST-M. Following three washes in TBST, blots were processed for chemiluminescent detection with enhanced luminescence reagents (Amersham). The blots were exposed to BioMax film (Kodak) for 15 mm.
To normalize protein loading, we first tried a standard protein assay reagent (Coomassie Plus; Pierce) and a new 1-tldotMetric Assay (Chemicon), but neither gave consistent results with the small amounts of protein we were using. As an a!ternative we developed a system to measure small protein samples using the SYPRO Red dye (Molecular Probes), which is used to visualize proteins on po!yacrylamide gels. Following electrophoresis of extracts from -20-30 animals on a bicine/Tris SDS-polyacrylamide gel, the gel was incubated for 15 mm in 0.01% SDS and then for 15 mm in a 1:5,000 dilution of SYPRO Red in 7.5% acetic acid. A 5-s exposure of the gel on a standard ultraviolet light box (using the SYPRO Orange/Red filter; Molecular Probes) was used to record the gel image. The photograph was scanned into Adobe Photoshop using a UMAX scanner. With use of the Gel Macros of the NIH Image program (version 1.6), the total amount of protein within a specified region of the gel was quantitated. Because the majority of protein in the sampie is concentrated in the upper region of this gel system, the 14.3-kDa molecular mass marker, which is readily visible with the SYPRO Red dye, was used to delineate the lower region of the lane to be measured. This technique produces a linear relationship among samples of 6.25-30 animals, although the variability increased with smaller numbers of animals. To normalize measurements among different gels, an aliquot from a large sample of animals was run on each gel. The protein concentration of this sample was measured using the Coomassie Plus assay, which allowed us to determine the protein concentration of the other samples based on their relative levels of staining with SYPRO Red.
RESULTS
A$ expression and amyloid formation in strains expressing wild-type~31-42
We have previously demonstrated that transgenic C. elegans strains can be engineered to express an unc-54//I 1-42 minigene designed to produce a potentially secretable form of human A/I in body wall muscle (Link, 1995) . This construct employs the promoter from the C. elegans major myosin gene unc-54 , a synthetic signal peptide, and a coding region derived from a human APP cDNA. These strains produce extensive muscle-associated anti-/I-immunoreactive deposits (see Fig. 2A ). Five additional transgenic strains (CL1 119-1121, 2122) were constructed using an alternative dominant marker gene, mtl-2/GFP, which results in constitutive intestinal expression of GFP, in conjunction with the unc-54//I 1-42 transgene; these lines show very similar patterns of immunoreactive deposits (data not shown).. To determine if these strains were expressing appropriately sized /I peptide, a quantitative immunobbot protocol was developed employing the anti-/I monocbonal antibody 4G8. As shown in result demonstrates that the synthetic signal peptide included in these constructs is being appropriately cleaved, resulting in the production of apparently unmodified human /3 peptide. Quantitation of the signal from these blots indicates that these lines produce 0.2-0.5 jig of A/I/mg of total protein. At these levels, theõ verall concentration of A/I in a single animal is roughly 10 jiM (see also Fig. 4) . Control transgenic strains (e.g., CL2122, which contains only the unc-54 expression vector and the mtl-2/GFP marker gene) lack immunoreactive deposits and produce no detectable signal on immunobbots.
To determine if unc-54//I 1-42 transgenic animals were producing /I-amyboid deposits, animals were stained with the amyloid-specific dyes Congo red and thioflavin S. Congo red staining of cut, unfixed animals resulted in the formation of classic green birefringent deposits when viewed under polarization optics (see Fig. 2C ). Thioflavin S staining of paraformaldehydefixed animals similarly produced fluorescent reactive deposits (see Fig. 2D ). The deposits observed in both staining regimes were on the order of 2-5 jim in size and were much fewer in number than immunoreactive deposits. (Thioflavin S-negative immunoreactive deposits may be equivalent to the immunoreactive nonamyboidic "presenile" deposits typically observed in the human brain.) Thioflavin S-reactive deposits were not observed in control transgenic or wild-type animals. For our samples, thioflavin S staining was significantly more reproducible and efficient than Congo red staining and thus was used for assaying amyboid formation in strains producing variant A/I.
A13 expression and amyloid formation in strains expressing A~variants
Five variants of A/I 1-42 were designed based on structural predictions of peptide folding and previous studies employing synthetic A/I subpeptides (see Fig.  1 ). Amino acid substitutions were made at residues predicted to lie in the central /3 sheet (Leu ' 7Pro, Leu 17-Va!) or in the C-terminal /3 sheet (Ala30Pro, Met35Cys, Met35Leu). Transgenes expressing variant A/I were constructed by in vitro mutagenesis of the unc-54/ /3 1-42 construct and verified by DNA sequencing.
Heritable transgenic lines were established by microinjection of transgene constructs along with dominant marker genes rol-6 or mtl-2/GFP. In C. elegans, initial transgenic lines resulting from DNA microinjection usually contain extrachromosoma! multicopy arrays of the injected DNAs and thus show incomplete meiotic and mitotic stability. Although transgenic animals can be readily distinguished from nontransgenic siblings by virtue of the phenotype resulting from the co-injected marker gene, for the majority of the transgene constructs, we were also able to derive completely stable, chromosomally integrated transgenic lines by screening y-irradiated transgenic populations.
Multiple independent transgenic lines were established for each of the variant transgenic constructs, and these lines were characterized by immunohistochemistry, immunoblot, and thioflavin S staining. All transgenic lines showed muscle-specific deposits of A/I immunoreactivity similar to that shown by unc-54//I 1-42 lines. Production of appropriately sized A/I was also confirmed for all the variant constructs by immunoblot, with the exception of the Leu t7Pro vanants, which failed to produce a detectable band, even though A/I expression was readily apparent by immunohistochemistry. (The lack of reactivity of the Leu '7Pro variants on immunoblots using antibody 4G8 may result because this substitution falls in the 4G8 epitope. Our ability to detect A/I immunoreactivity in these variant strains by immunohistochemistry may result because this technique is more sensitive or the 4G8 epitope is more severely altered by the Leu 17Pro substitution when A/I is in a denatured form.) The thioflavin S reactivity of these strains is shown in Table  1 . Strikingly, all lines expressing the Leu '7Pro or Met 35Cys variants failed to produce thioflavin S deposits (see Fig. 3 ).
To establish that the differences in amyloid formation among the transgenic lines result from qualitative, as opposed to quantitative, differences, A/I expression levels for chromosomally integrated lines were deter- 
0.0°S
trains with designation numbers of <2000 contain extrachromosomal transgenic arrays; those with designation numbers of >2000 contain chromosomally integrated transgenes.
"++"
indicates >95% of animals of a given strain contain multiple thioflavin S-reactive deposits; "+" indicates 30-80% ofanimals contain multiple thioflavin S deposits; "-" indicates 0% of animals contain multiple thioflavin S-reactive deposits.
'Thioflavin S deposits were counted in the anterior portion of 20 adult animals for each of the chromosomally integrated transgenic lines. Numbers represent mean plaque count ±SEM.
"For both strains CL21 15 and CL31 15, 2 of 20 animals were observed to have one deposit. showed no significant difference in amyloid expression among these strains. Thus, the inability of strains expressing the Met 35Cys substitution to form amyloid deposits results from a qualitative change in the structure of this variant.
FIG. 3. Thioflavin S-reactive deposits in transgenic animals
Aj3 expression and amyloid formation in animals expressing novel J3-dimer construct Our experimental approach allows the production of A/I variants that have not been examined in other systems. One such variant is a single-chain /I dimer, which consists of two tandem copies of /3 1-42 joined by a synthetic 15-residue glycine-nch flexible linker (see Fig. 5A ). Similar "hinge" regions have been successfully employed to link heavy-and light-chain immunoglobulins into functional single-chain antibody molecules (Batra et a!., 1990) . If the formation of antiparalle! /I dimens is a kinetically limiting step in the formation of amyloid fibnils, then "tethering" two /I-dimer molecules together with the linker might significantly increase rate at which these dimers form, thereby producing a hyperaggregating variant. Transgenic lines expressing the unc-541/I-dimer construct show muscleassociated immunoreactive deposits similar to those shown by the A/I transgenic lines (see Fig. 5B ). Animals expressing the /I-dimer transgene produce high levels of a dimer-sized protein as visualized by immunoblot (see Fig. SC ). Quantitation of these blots indicates that integrated /I-dimer line CL2109 expresses 11.3 ±4.0 ng of A/I/jig of total protein, whereas the /I-dimer line CL3109 expresses 10.2 ±4.0 ng of A/Il jig of total protein. These A/I levels are an order of magnitude greater than any of the other transgenic lines we have measured. Nevertheless, neither of these /Idimer lines produces any thioflavin S-reactive deposits (see Fig. SD) . Thus, linking A/I 1-42 sequences into a single-chain dimer completely abrogates amyloid formation in these transgenic animals.
DISCUSSION
We have demonstrated the presence of /I-amyloid deposits in a transgenic C. elegans model system ex -FIG. 4 . /I-Peptide expression levels in transgenic animals expressing wild-type or variant /I 1 -42. Quantitative immunoblots were used to assay extractable A/I from chromosomally integrated transgenic lines expressing wild-type or variant A/I (see Materials and Methods). Replicates were performed on independently collected and processed animal samples, which were also generally quantitated on independent immunoblots. Strains CL2005, CL2006, and CL2120 express wild-type /3 1-42; strain CL2085 expresses the Ala30 Pro A/I variant; and strains CL2115, CL3115, and CL4115 express the Met35Cys A/I variant. pressing human A/I. The A/I transgene expressed in these animals contains a synthetic signal peptide, immediately preceding the A/I coding sequence, to direct the expressed peptide to the secretory pathway. We observed both efficient cleavage of the signal peptide and perinuclear distribution of A/I immunoreactivity (particularly in larval animals), suggesting that the expressed A/I is being appropriately routed to the endoplasmic reticulum (C. D. Link, unpublished observations) . The A/I expressed in these animals appears full length as observed by immunoblot (although we have not confirmed the N-terminal sequence with specific antibodies), and A/I expressed by strains CL2005 and CL2006 reacts with antibodies specific for the A/3 1-42 C terminus when assayed by sandwich ELISA (C. Eckman and S. Younkin, personal communication) . Formation of amyloid deposits occurs rapidly (i.e., in 3-day-old animals) in comparison with transgenic mouse models (Games et a!., 1995; Hsiao et a!., 1996) . Although these amy!oid deposits are clearly muscle associated, the cortical nature of these deposits (i.e., lying near the circumference of the body) suggests they may form distally in the secretory pathway of the muscle cells or extracellularly on the surface of the muscle cells. (Resolution of the exact location of the /I-amyloid deposits will require ultrastructural analysis.) We have used the highly reproducible formation of /I-amyloid deposits in animals expressing A/I 1-42 to investigate in vivo the role of specific A/I residues in /I-amyloid formation.
All independent transgenic lines expressing the Leu17Pro substitution failed to produce thioflavin S-reactive deposits, in contrast to lines expressing the conservative Leu '7Val substitution. These results are consistent with previous studies that assayed the aggregation of synthetic A/I peptides containing nonconservative substitutions in the hydrophobic 17-21 core sequence (Hilbich et a!., 1992; Soto et a!., 1995a; Wood et a!., 1995) . Similarly, a Phe t9Thr substitution has been found to block plaque growth competence, another assay for the amyloidic potential of A/I (Esler et a!., 1996) . Although we could not quantify A/I levels in the Leu '7Pro lines (likely due to this substitution interfering with antibody 408 binding on immunoblots), we think it is likely that the absence of amyloid deposits in these lines results from a specific alteration in A/I structure due to this substitution. As proline substitutions disrupt /3-sheet folding, our results support the existence of the predicted central /3-sheet structure in amyloidic A/I and demonstrate the importance of this region for in vivo amyloid formation.
All independent transgenic lines expressing the Met35Cys substitution also failed to produce thioflavin Sreactive deposits, whereas lines expressing the conservative Met35Leu variant all produced amyloid deposits (albeit at reduced levels relative to wild-type A/I lines; see below). Integrated lines expressing the Met 35Cys variant have comparable A/I levels as strains expressing wild-type A/I, so the inability of this variant to form amyloidic deposits must result from structural changes in the expressed peptide. These results are contrary to those of Pike et a!. (1995) , who reported that a Met 35Leu substitution strongly reduced aggregation of an A/I 25-35 peptide, whereas a Met35Cys substitution significantly increased the aggregation (and neurotoxicity) of this peptide in comparison with the control wild-type peptide. This discrepancy is not trivial, as Met35 has been shown to be important in an in vivo A/I 25-35 toxicity model (Chen et a!., 1996) and has been proposed to be a key residue for aggregation and neurotoxicity, based on a free radical model of A/I toxicity (Hensley et a!., 1994) . Seilheimer and colleagues (1997) , who used an Escherichia coli expression system to produce full-length wild-type and variant A/I 1-42, reported that all Met35 substitutions tested (Leu, Ser, Gin, or Glu) resulted in reduced aggregation. We suggest that the aggregation of the Met35Cys peptide observed by Pike et a!. (1995) may be a result of their use of the A/I 25-35 subpeptide, in which the Cys substitution occurs at the carboxy terminus. Amidation of the carboxy terminus of A/I 25-35 significantly shifts its structure (Tenzi et a!., 1994) , illustrating the importance of the carboxy terminus in the structure of this A/I subpeptide. As A/I peptides terminating at Met35 have not been identified in the human brain, it may be misleading to apply structural predictions based on studies of A/I 25-35 (or other subpeptides) to in vivo A/I. Our results, employing full-length A/I, are nevertheless consistent with previous studies implicating Met35 as an important residue for the formation of amyloidic A/I. The four transgenic lines expressing an Ala 30Pro variant a!! produced some thioflavin S-reactive deposits. This variant, like the Leu 17Pro substitution described above, was designed to disrupt a predicted /I sheet of A/I (see Fig. 1 ). An Ala30Pro substitution has been previously reported to disrupt fibril formation of A/I 25-35 (Wetzel et al., 1994) . Unlike the Leu'7Pro variant, A/I Ala 30Pro still retains amyloidic potential in our system. However, lines expressing this variant consistently showed fewer thioflavin S deposits than lines expressing wild-type A/I. Typically, 20-40% of animals from a given Ala30Pro line (including the completely stable, chromosomally integrated line CL2085) failed to produce detectable thioflavin S deposits, suggesting that this substitution does decrease the amy!oidic capacity of A/I. However, given that Ala30Pro strain CL2085 shows slightly lower overall levels of A/I, some of this reduction in thioflavin S deposits might result from quantitative, as opposed to qualitative, differences. Lines expressing the Met 35Leu substitution also consistently had fewer deposits than lines expressing wild-type A/I, which may also be indicative of a somewhat reduced amyloidic capacity of this variant.
Transgenic lines expressing a novel single-chain A/I dimer also fail to form thioflavin S-reactive deposits, despite expressing very high levels of this variant. Our estimates of 10 ng of A/I/jig of protein are based on a direct comparison to the immunoblot signal produced by synthetic A/I 1-40. As each A/I dimer has two potential 4G8 epitopes, the molar amounts may be half of an equivalent mass amount of A/I, which would still be an order of magnitude greater than the A/I levels expressed by the other strains. The mechanism by which linking A/I monomers blocks aggregation is unclear. Perhaps the linker region is insufficiently long or flexible to allow appropriate alignment of the A/I monomers or the linker sterically hinders multimerization of A/I into amyloid. Alternatively, the three serine residues in the linker may change the overa!! charge~tir hydrophobicity of the peptide enough to preclude amyloid formation. Distinguishing between these and other possibilities will require analysis of an additional series of linker variants. Although the interpretation of the A/I-dimer results is not straight-forward, we find it very intriguing that we commonly observe higher molecular mass immunoreactive species on A/I-dimer immunoblots (see Fig. SC, lane 3) . These higher molecular mass species are the appropriate size to correspond to aggregates containing two or four A/I-dimer molecules. (An A/I-dimer-sized species is typically observed on these denaturing gels when boiled synthetic A/I 1-40 is run as a standard, as seen in Fig. SC, lane 1. ) This observation suggests that the A/I dimer is competent to form denaturationresistant multimers, but that this aggregation pathway does not lead to the formation of amyloid.
An additional rationale for the construction and analysis of A/I variants in our transgenic system was to search for "nontoxic" variants that could serve as appropriate controls for physiological studies of the effects of wild-type A/I on C. elegans. As previously reported, animals with muscle-specific expression of wild-type A/I contain larval vacuoles and show a progressive paralysis (Link, 1995 We have demonstrated that this transgenic C. elegans system can be used for in vivo structure/function studies concerning the role of specific residues in /3-amyloid formation, and we anticipate other A/I variants can be profitably scrutinized using this system. The rapid formation of amyloid in these transgenic animals also suggests that they might also be useful for screening drugs or treatments designed to inhibit amyloid formation.
